Vertex Pharmaceuticals Incorporated VRTX

NASDAQ US Health Care Biotechnology

$549.94 ▼ -0.17% ($-0.93)

Index member: S&P 500

Open $548.39

Prev Close $550.87

Day Range $543.77 – $551.86

52W Range $406.67 – $568.67

Market Cap $141.65B

P/E (TTM) 34.89

Beta 0.24

EPS (TTM) $15.54

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-07-24
Shares Out.	253,460,000
Website	vrtx.com/ ↗
Phone	16173416393
Employees	6,400
Revenue	$3.44B
Gross Profit	$2.91B
Net Income	$653.6M
Free Cash Flow	$3.20B
Total Assets	$32.74B
Total Liabilities	$11.83B
Equity	$20.91B

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Vertex Pharmaceuticals Incorporated is a publicly traded company under the ticker symbol VRTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.